Mutations in Mycobacterium tuberculosis that Confers Resistance to First Line and Second Line Anti Tuberculosis agents in Western Kenya

Abstract

BACKGROUND

Tuberculosis drug resistance remains a global, regional as well as a national public health concern, and is driven by point mutations in the Mycobacterium tuberculosis genome. However, their frequencies vary geographically and that affects the general applicability of antimicrobial agents as opposed to regional tailored or individualized chemotherapy.